Joao Paulo Steffens

Prof. Joao Paulo Steffens

Department of Stomatology, Universidade Federal do Paraná, Curitiba, Paraná, Brazil
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2026 in Bone Research
Verified
Journal Article
Open access
RMRafael Scaf de Molon
Rafael Scaf de Molon
Rolando VernalRolando Vernal
Rolando Vernal
GOGabriela Ezequiel Oliveira
Gabriela Ezequiel Oliveira
Joao Paulo SteffensJoao Paulo Steffens
Joao Paulo Steffens
EEEdilson Ervolino
Edilson Ervolino
STSotirios Tetradis
Sotirios Tetradis
Bone resorption is a vital physiological process that enables skeletal remodeling, maintenance, and adaptation to mechanical forces throughout life. While tightly regulated under the physiological state, its dysregulation contributes to pathological conditions such as osteoporosis, rheumatoid arthritis, and periodontitis. Periodontitis is a highly prevalent chronic inflammatory disease driven by dysbiotic biofilms that disrupt the oral microbiome, leading to the progressive breakdown of the periodontal ligament, cementum, and alveolar bone and ultimately resulting in tooth loss. This review outlines the molecular and cellular mechanisms underlying periodontitis, focusing on osteoclastogenesis, the differentiation and activation of osteoclasts, the primary mediators of bone resorption. Key transcriptional regulators, including NFATc1, c-Fos, and c-Src are discussed alongside major signaling pathways such as Mitogen Activated Protein Kinase (MAPK), Janus Tyrosine Kinase/Signal Transducer and Activator of Transcription (JAK/STAT), Nuclear Factor Kappa B (NF-κB), and Phosphoinositide 3-kinase (PI3K)/Akt, to elucidate their roles in the initiation and progression of periodontal bone loss. These pathways orchestrate the inflammatory response and osteoclast activity, underscoring their relevance in periodontitis and other osteolytic conditions. Hallmark features of periodontitis, including chronic inflammation, immune dysregulation, and tissue destruction are highlighted, with emphasis on current and emerging therapeutic strategies targeting these molecular pathways. Special attention is given to small molecules, biologics, and natural compounds that have the potential to modulate key signaling pathways. Although advances in understanding these mechanisms have identified promising therapeutic targets, translation into effective clinical interventions remains challenging. Continued research into regulating bone-resorptive signaling pathways is essential for developing more effective treatments for periodontitis and related inflammatory bone diseases.

1 October 2015 in Journal of Periodontology
Verified
Journal Article
Closed access
Joao Paulo SteffensJoao Paulo Steffens
Joao Paulo Steffens
XWXiaoshan Wang
Xiaoshan Wang
JSJacqueline R. Starr
Jacqueline R. Starr
LSLuis Carlos Spolidorio
Luis Carlos Spolidorio
TDThomas E. Van Dyke
Thomas E. Van Dyke
AKAlpdogan Kantarci
Alpdogan Kantarci
Background: Sex hormones are linked to inflammation and bone turnover. The goal of this study is to explore the association between sex hormone levels and periodontitis in men using data from the third National Health and Nutrition Examination Survey (NHANES III).Methods: Data from 755 men (aged ≥30 years), including serum levels of testosterone, estradiol, sex hormone binding globulin, and androstenediol glucuronide, were analyzed. Calculated bioavailable testosterone (CBT) and estradiol‐to‐testosterone ratio were calculated. Periodontitis was defined using the latest classification of extent and severity of periodontitis for NHANES data (≥2 interproximal sites with ≥3 mm attachment loss, ≥2 interproximal sites with probing depth [PD] ≥4 mm not on the same tooth, or one site with PD ≥5 mm). Sex hormones were evaluated as categorized and continuous variables. Correlations between the presence and severity of periodontitis and levels of sex hormones were determined and expressed as odds ratios (ORs).Results: When adjusted for confounding factors, high total testosterone (TT) and CBT levels correlated with both the prevalence (OR [95% confidence interval (CI)], 2.1 [1 to 4.5] and 3.9 [1 to 14.8], respectively) and severity (OR [95% CI], 2.1 [1 to 4.3] and 3.4 [1.2 to 9.8]) of periodontitis. When continuous variables were used, the ORs (95% CIs) for presence and severity of periodontitis were 1.4 (0.6 to 3.3) and 1.5 (0.6 to 3.6) for TT and 1.3 (0.9 to 1.9) and 1.3 (0.9 to 1.8) for CBT, respectively.Conclusions: These findings are consistent with the existence of an association of periodontitis with sex hormone levels, especially testosterone, in men.

13 February 2014 in Hormone and Metabolic Research
Verified
Journal Article
Closed access
PDF file
Joao Paulo SteffensJoao Paulo Steffens
Joao Paulo Steffens
BHBruno S Herrera
Bruno S Herrera
LCL. S. Coimbra
L. S. Coimbra
DSD. N. Stephens
D. N. Stephens
CJCarlos Rossa Jr
Carlos Rossa Jr
TDT. E. Van Dyke
T. E. Van Dyke
This study evaluated the alveolar bone response to testosterone and the impact of Resolvin D2 (RvD2) on testosterone-induced osteoblast function. For the in vivo characterization, 60 male adult rats were used. Treatments established sub-physiologic (L), normal (N), or supra-physiologic (H) concentrations of testosterone. Forty rats were subjected to orchiectomy; 20 rats received periodical testosterone injections while 20 rats received testicular sham-operation. Four weeks after the surgeries, 10 rats in each group received a subgingival ligature around the lower first molars to induce experimental periodontal inflammation and bone loss. In parallel, osteoblasts were differentiated from neonatal mice calvariae and treated with various doses of testosterone for 48 h. Cell lysates and conditioned media were used for the determination of alkaline phosphatase, osteocalcin, RANKL, and osteoprotegerin. Micro-computed tomography linear analysis demonstrated that bone loss was significantly increased for both L and H groups compared to animals with normal levels of testosterone. Gingival IL-1β expression was increased in the L group (p<0.05). Ten nM testosterone significantly decreased osteocalcin, RANKL, and OPG levels in osteoblasts; 100 nM significantly increased the RANKL:OPG ratio. RvD2 partially reversed the impact of 10 nM testosterone on osteocalcin, RANKL, and OPG. These findings suggest that both L and H testosterone levels increase inflammatory bone loss in male rats. While low testosterone predominantly increases the inflammatory response, high testosterone promotes a higher osteoblast-derived RANKL:OPG ratio. The proresolving mediator RvD2 ameliorates testosterone-derived downregulation of osteocalcin, RANKL, and OPG in primary murine osteoblasts suggesting a direct role of inflammation in osteoblast function.

1 August 2018 in Revista de Odontologia da UNESP
Verified
Journal Article
Open access
Joao Paulo SteffensJoao Paulo Steffens
Joao Paulo Steffens
RMRosemary Adriana Chierici Marcantonio
Rosemary Adriana Chierici Marcantonio

1 August 2010 in Journal of Periodontology
Verified
Journal Article
Closed access
Joao Paulo SteffensJoao Paulo Steffens
Joao Paulo Steffens
FSFábio André Santos
Fábio André Santos
RSRafael Sartori
Rafael Sartori
GPGibson Luiz Pilatti
Gibson Luiz Pilatti
Background: Several anti‐inflammatory drugs have been used to reduce pain and discomfort after periodontal surgeries. This study evaluates the efficacy of using etoricoxib and dexamethasone for pain prevention after open‐flap debridement surgery.Methods: For this prospective, double‐masked, crossover, placebo‐controlled, randomized clinical trial, open‐flap debridement surgeries were performed on 15 patients (eight males and seven females, age range 20 to 56 years: mean age ± SD: 40 ± 9.7 years) who presented with chronic periodontitis after non‐surgical periodontal therapy at three quadrants. Each patient underwent three surgical procedures at intervals of 30 days and received one of the following premedication protocols 1‐hour before surgery: group 1 = placebo, group 2 = 8 mg dexamethasone, and group 3 = 120 mg etoricoxib. Rescue medication (750 mg acetaminophen) was given to each patient who was instructed to take it when necessary. Pain intensity and discomfort were evaluated by a 101‐point numeric rate scale and a four‐point verbal rate scale, respectively, hourly for the first 8 hours after surgery and three times a day on the following 3 days.Results: The results demonstrate that groups 2 and 3 present reduced postoperative pain‐intensity levels compared to group 1. There were statistically significant differences at the 4, 5, 6, 7, and 8 hour‐periods after surgery (Friedman test; P <0.05). Furthermore, rescue‐medication intake was significantly lower for groups 2 and 3 than for group 1 (analysis of variance; P <0.02).Conclusion: The adoption of a preemptive medication protocol using etoricoxib or dexamethasone may be considered effective for pain and discomfort prevention after open‐flap debridement surgeries.

1 January 2017 in Journal of Periodontology
Verified
Journal Article
Closed access
MBMaha A. Bahammam
Maha A. Bahammam
RKRayyan A. Kayal
Rayyan A. Kayal
DADhafer S. Alasmari
Dhafer S. Alasmari
MAMai S. Attia
Mai S. Attia
LBLaila A. Bahammam
Laila A. Bahammam
Joao Paulo SteffensJoao Paulo Steffens
Joao Paulo Steffens
Background: Postoperative pain is a potential adverse side effect of oral surgeries, and attempts should be made to prevent or minimize it. This study compares efficacy of preemptive ibuprofen and dexamethasone protocols for pain prevention or control after surgical implant placement.Methods: This prospective, double‐masked, parallel‐group, placebo‐controlled, randomized clinical trial included 117 patients with planned dental implant placement. Patients were assigned to receive one of three different protocols: 1) 600 mg ibuprofen 1 hour before surgery and another 600 mg 6 hours after the first dose; 2) 4 mg dexamethasone 1 hour before surgery and another 4 mg 6 hours after the first dose; or 3) placebo. Rescue medication (1,000 mg acetaminophen) was made available to each patient, and they were instructed to take it as necessary. Pain intensity was evaluated via a 101‐point numeric rating scale and a visual analog scale, and discomfort was evaluated using a four‐point verbal rating scale hourly for the first 8 hours after surgery and three times daily for the following 3 days.Results: Ibuprofen and dexamethasone significantly reduced pain (Kruskal–Wallis; P <0.05) up to 3 days after surgery and discomfort (P <0.05) up to 2 days after surgery compared with placebo treatment. Both treatments reduced the number of painkillers taken and increased time before the first painkiller was taken (P <0.01).Conclusion: Steroidal dexamethasone is as effective as non‐steroidal ibuprofen for preventing or controlling postoperative pain and discomfort after surgical implant placement.